XML 85 R56.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Collaborative Arrangements and Licensing Agreements, Metagenomi (Details) - Metagenomi [Member] $ in Millions | 12 Months Ended
--- | ---
Dec. 31, 2022 USD ($) Target
Collaborative Arrangement and Licensing Agreement [Abstract] |
Number of targets to be researched, developed and commercialized | Target | 4
Number of additional targets to be researched, developed and commercialized | Target | 4
Payment to license technology | $ | $ 80
Research and development expense | $ | $ 80

X
- References No definition available. + Details
Name: | ions_CollaborativeArrangementAndLicensingAgreementAbstract
Namespace Prefix: | ions_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of additional targets to be researched, developed and commercialized under the collaboration agreement upon achievement of certain development milestones. + References No definition available. + Details
Name: | ions_NumberOfAdditionalTargetsToBeResearchedDevelopedAndCommercialized
Namespace Prefix: | ions_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition The number of targets to be researched, developed and commercialized under the collaboration agreement. + References No definition available. + Details
Name: | ions_NumberOfTargetsToBeResearchedDevelopedAndCommercialized
Namespace Prefix: | ions_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of cash outflow to license technology under a collaboration and license agreement. + References No definition available. + Details
Name: | ions_PaymentToLicenseTechnology
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1 + Details
Name: | us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_MetagenomiLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |